seqHPV NGS Genotyping

Identification of Human papilloma virus (HPV) infection is an  important  tool  for  screening  and  prevention of carcinoma of the cervix, as nearly  all  of  cervical  cancer  cases (99.7%) worldwide are associated with HPV infection.

seqHPV™ HPV Genotyping Test combines self-sampling technology and NGS-based genotyping assay to accurately detect various HPV genotypes from both high-risk and low-risk group, serve as the primary screening test for cervical cancer.


  • Full Coverage of High-Risk HPV Associated with Cervical Cancer
    Screening test covering all high-risk HPV genotypes associated with cervical cancer as per recommended by World Health Organization
  • Flexible Sampling Methods
    Applicable for both professional physician-sampling and self-sampling method with similar outcome.
  • Diversified Sample Preservation Methods
    Test compatible with wet and dry swab specimen
  • High throughput
    Ideal for screening program by tested up to 6000 samples on validate platforms at low cost
  • Flexible applications for clinical and research purpose
Screens for

14 high risk HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 2 low risk HPV genotypes 6 and 11.

Sample requirement

Cervical exfoliated cell (prepared on DNA storage card or preservation fluid)